May 15, 2024
Newsfile Corp. July 19, 2022·5 min read Calgary, Alberta–(Newsfile Corp. – July 19, 2022) – NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System (“CNS”) indications, announced the signing of a Material
The company is developing a novel, non-invasive, bio-guided treatment to restore function of patients with acute spinal cord injuries. read more
https://finance.yahoo.com/news/nurexone-provides-corporate-120000076.html
SHARE TWEET SHARE EMAILThe Israeli BioTech company tackling SCI injury treatment recently began trading on the TSXV Approximately 17,700 new spinal cord injuries (SCI) take place each year just in the US alone, most of which are the result of vehicle, work and sporting accidents and falls. Calculating the impact
An estimated 17,700 new spinal cord injuries (SCI)occur each year in the United States alone, most of which are the result of vehicle, work and sporting accidents and falls. Calculating the impact of spinal cord injuries on people worldwide requires a broader sample, but the World Health Organization (WHO) states